Glucose Metabolism and Coronary Heart Disease in Patients with Normal Glucose Tolerance

JAMA

Volumn 291, Issue 15, 2004, Pages 1857-1863

  Sasso, Ferdinando C ^a   Carbonara, Ornella ^a   Nasti, Rodolfo ^a   Campana, Biagio ^a   Marfella, Raffaele ^a   Torella, Michele ^a   Nappi, Giannantonio ^a   Torella, Roberto ^a   Cozzolino, Domenico ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCOSYLATION; HOMEOSTASIS; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; UNIVERSITY HOSPITAL;

EID: 1942510654     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.15.1857     Document Type: Article

References (34)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors in the Framingham Study. JAMA. 1978;38:46-51.
2. Pan WH, Cedres LB, Liu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 1986;123:504-516.
3. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
4. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-373.
5. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
6. American Diabetes Association. ADA Clinical Practice Recommendations 2002: management of dyslipidemia in adults with diabetes. Diabetes Care. 2002;25(suppl 1):S74-S77.
7. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
8. Saydah SH, Loria CM, Eberhardt M, et al. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care. 2001;24:447-453.
9. Modan M, Meytes D, Rozeman P, et al. Significance of high HbA1 levels in normal glucose tolerance. Diabetes Care. 1988;11:422-428.
10. Park S, Barrett-Connor E, Wingard DL, et al. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: the Rancho Bernardo Study. Diabetes Care. 1996;19:450-456.
11. De Vegt F, Dakker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-931.
12. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
13. Pyörälä M, Miettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-years follow-up results of the Helsinki Policemen Study. Circulation. 1998;98:398-404.
14. Fujiwara R, Kutsumi Y, Hayashi T, et al. Relation of angiographically defined coronary artery disease and plasma concentration of insulin, lipid and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol. 1995;75:122-126.
15. Farrer M, Fulcher G, Albers CJ, et al. Patients undergoing coronary artery bypass graft surgery are at high risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. Metabolism. 1995;44:1016-1027.
16. Donahue RP, Abbott RD, Reed DM, et al, Honolulu Heart Program. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Diabetes. 1987;36:689-692.
17. Kowalska I, Prokop J, Bachorzewska-Gajewska H, et al. Disturbance of glucose metabolism in men referred for coronary arteriography. Diabetes Care. 2001;24:897-901.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1999;22(suppl 1):S5-S19.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
20. De Fronzo RA, Tobin JA, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
21. Howard G, Bergman R, Wagenknecht LE. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model." Ann Epidemiol. 1998;8:358-369.
22. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(suppl 4):5-40.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
24. Califf RM, Phillips HR III, Hindman MC, et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol. 1985;5:1055-1063.
25. Vlassara H, Brownlee M, Manogue KR, et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodelling. Science. 1988;240:1546-1548.
26. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest. 1995;96:1395-1403.
27. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87:432-438.
28. Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol. 1993;143:1649-1656.
29. Kume S. Immunohistochemical and ultrastructural detection of AGE in atherosclerotic lesions. Am J Pathol. 1995;147:654-667.
30. Kilhovd BK, Berg TJ, Birkeland KI, et al. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care. 1999;22:1543-1548.
31. Kanauchi M, Hashimoto T, Tsujimoto N. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care. 2001;24:1620-1623.
32. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257-267.
33. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1-9.
34. Graham MM, Faris PD, Ghali WA, et al. Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J. 2001;142:254-261.